CMP: ₹ 1695

Target: ₹ 1520 (-10%)

Target Period: 12 months

January 18, 2023

Business in core markets continues to face headwinds

About the stock: Mastek Ltd (Mastek) offers data, apps, cloud services to public & private enterprise in the UK, US, Middle East, Asia Pacific and India.

- The company's recent acquisition of Evosys has enabled Mastek to provide end-to-end solutions and improves margins from ~14% to 21%
- Net debt free and healthy double digit return ratio (with RoCE of 20%)

Q3FY23 Results: Reported weak organic growth in Q3.

- Revenue grew 3.1% QoQ in CC terms with flat organic growth while in dollar terms revenue grew 2.6% QoQ
- EBITDA margin was flat sequentially at 17.3%
- Reported 12M order backlog of US\$206.2 mn, up 10.2%QoQ

What should investors do? Mastek's share price has grown by \sim 4.1x over the past five years (from $\sim ₹$ 414 in January 2018 to $\sim ₹$ 1,695 levels in January 2023).

• We change our rating on the stock from HOLD to REDUCE

Target Price and Valuation: We value Mastek at ₹ 1,520 i.e. 13x P/E on FY25E EPS.

Key triggers for future price performance:

- Growth in new logo acquisition, increasing deal size, expansion of sales & marketing and market share gains to drive revenues
- Management change in the US region may help it to grow stronger & achieve desired revenue mix
- Acquisition of MST Solutions will help drive growth in the US region
- Expect revenues to grow at 8.2% CAGR in FY22-25E

Alternate Stock Idea: Apart from Mastek, in our IT coverage we also like Infosys.

- Key beneficiary of improved digital demand, industry leading revenue growth & healthy capital allocation prompt us to be positive
- BUY with a target price of ₹ 1,730

Source: Company, ICICI Direct Research

Picici direct Research

REDUCE

Mastek

Particulars Particulars Amount Market Capitalization (₹ Crore) 4.818.9 Total Debt (₹ Crore 190.3 Cash and Investments (₹ Crore) 781.9 EV (₹ Crore) 4.227.2 52 week H/I 3413/1490 Equity capital (₹ Crore) 15.0 Face value 5.0

Shareholulliy pattern								
	Dec-21	Mar-22	Jun-22	Sep-22				
Promoters	38	37	37	37				
FII	5	7	8	13				
DII	7	7	6	4				
Public	50	49	49	46				

Price Chart



Recent Event & Key risks

- Acquired 31 new logos in Q3 and 12M order back log up by 29.7% YoY in CC terms
- Key Risk: (i) US business ramp up better than expectation, (ii) Rebound in organic revenues

Research Analyst

Sameer Pardikar sameer.pardikar@icicisecurities.com Sujay Chavan sujay.chavan@icicisecurities.com

Key Financial Summary							
₹ Crore	FY21	FY22	5 Year CAGR (FY17-22)	FY23E	FY24E	FY25E	3 Year CAGR (FY22-25E)
Net Sales	1,722	2,184	31.3	2,266	2,525	2,768	8.2
EBITDA	364	463	57.0	408	462	518	3.8
EBITDA Margins (%)	21.2	21.2		18.0	18.3	18.7	
Net Profit	209	295	55.5	263	311	349	5.8
EPS (₹)	82	104		88	103	116	
P/E	20.7	16.3		19.3	16.4	14.6	
RoNW (%)	24.4	27.5		20.5	20.1	19.1	
RoCE (%)	21.5	26.7		21.2	21.3	20.7	

ICICI Securities – Retail Equity Research

Key takeaways of quarter and conference call highlights

- The company reported growth of 3.1% QoQ growth in CC term while dollar revenue came in at US\$80.1 mn, up 2.6% QoQ with full quarterly revenue contribution of Metasoftech Solutions LLC, US (MST). The company indicated that the organic revenue growth was flattish, implying a weak performance of organic business in YTD December 2022. In rupee terms, revenue was at ₹ 658.7 crore, up 5.3% QoQ
- Geography wise UK (58.9% of the mix) reported muted growth of 0.1% QoQ while growth was driven by the US (27.8% of mix, up 360 bps QoQ) reporting growth of 21.2% QoQ. Growth was aided by full quarter contribution of MST. ME region also reported steady 10.6% sequential growth
- Vertical wise government (41.4% of the mix) reported growth of 3.2% QoQ while financial services, health and manufacturing & tech reported growth of 13.3%, 14.4% & 8.2%, respectively. Retail sector revenue declined 6% QoQ while the company indicated that retail segment was impacted due to weakness in some clients due to macro headwinds & impact of furloughs
- The company reported flattish EBITDA margin of 17.3% compared to Q2. Mastek indicated that though the supply side challenges have started to ease out, margins were impacted by continuance of sub-contractor expenses as per the requirement of UK NHS business and onetime provision for certain doubtful debts
- The company indicated that it expects EBITDA margins to improve from Q4 onwards and indicated that the operating margin levers will be easing of supply side challenges due to lower attrition and increase in utilisation as freshers are being deployed on projects. The company indicated that it is aiming for high teens margin for FY24 in the range of 17-19%. Mastek also indicated that since it is targeting high growth in revenues in the medium term it will invest the additional margins earned above 19% back in business
- The company indicated that the organic health business in UK, which is contributed majorly by NHS, is still under stress due to a change in leadership at the organisation level and shortage of workers. Mastek indicated that pain in the business is likely to sustain in the next two to three quarters. The company indicated that it lost budgeted revenue potential of ~US\$24 mn in NHS business till YTD December 2022. Mastek also indicated that it has been taking a few steps to mitigate the issue it is facing in NHS business by diversifying into other department verticals wherein it also won three deals but the ramp up for the same is yet to happen
- In the US organic business, the company indicated that its progress was below expectations as there was a delay in client mining & order booking. The company also indicated that performance was impacted due to the discontinuing of CX business by Oracle. However, on the inorganic front, the acquisition of MST has accelerated its overall growth in the US region. The company indicated that MST operates mainly in the health, government & manufacturing verticals and as the integration progresses it is witnessing cross-sell opportunities among the MST & Mastek's client. The company also indicated that it looking to grow aggressively in the US region both on the organic and inorganic front and expects a quarterly revenue run rate to hit US\$24-25mn in Q4FY23
- In the Middle East region, the company indicated that it is witnessing increased traction after the Russia-Ukraine border conflict started. Mastek indicated that it is seeing increased demand for its services in the health segment in the Saudi Arabia and Dubai regions. The company indicated that it is looking to cut the tail of long clients, looking to focus on top 20-25 clients here and cut out low margin business here

- The company indicated that its 12M backlog has increased by 10.2% QoQ to US\$206.2 mn while in CC terms the growth was 5.3%. Mastek indicated that the demand momentum has picked up at the end of the Q3 and the deals that were delayed in H1 are getting closed. The company also indicated that it has closed four to five deals of US\$5 mn+. Also, the Oracle pipeline in the US & ME region is looking strong. The company also indicated that since the macro environment has deteriorated compared to last year, clients are reprioritising the cost optimisation & efficiency deals over discretionary spending along with breaking the large size deals into smaller ones. The company indicated that this will also help it to win some deals in future and provides a stable outlook in the medium term driven by growth in the UK & US regions
- The company added 31 new clients in this quarters taking the total client's addition for 9MFY23 to 84. The company indicated that out of the 31 clients that it added, six have more than US\$1bn annual revenues. It will also provide them an opportunity to further strengthen their wallet share with them
- The company's LTM attrition continue to moderate. In Q3, the LTM attrition declined by 90 bps QoQ to 23.3% as the supply side challenges are easing out. Mastek indicated that utilisation declined by 120 bps QoQ to 73.7%. The company indicated that it aims to improve the utilisation to the level of 75-78% and will be one of the key levers for margin improvement
- The company's net headcount during the quarter declined by 123 taking the total headcount to 5,687 employees. Mastek indicated that the drop in employees was due to backfilling of open positions by internal realignments. The company indicated that it had hired good chunk of fresher in H1FY23 and after training they are being deployed in the projects in a gradual manner. It also indicated that it plans to make leadership changes in the US region and hire a sales team to ramp up the sales opportunity in the region
- The company mentioned that during the quarter it made a strategic investment in VolteoEdge, a SaaS company with an Enterprise ready Edge Intelligence Platform that works on data & connected devices for data extraction. The company indicated that these solutions along with the company's will provide prospective solution for ServiceNow clients
- The company mentioned that during the quarter it has purchased 33,446 CCPS of its subsidiary for a consideration of ₹ 120 crore. Mastek further indicated that the consideration is to be paid by ₹ 40 crore in cash with balance ₹ 80 crore by issuing equity shares
- The company declared an interim dividend of ₹ 7 per share and announced that record date for determining the eligible shareholders for payment of dividend will be February 1, 2023

	Q3FY23	Q3FY22	YoY (%)	Q2FY22	QoQ (%)	Comments
Revenue in USD mn	80.1	73.6	8.8	78.1	2.6 ^R re	evenue growth of 3.1% QoQ in CC terms with organic growth emaining flat
Revenue	658.7	551.9	19.3	625.3	5.3	
Employee expense	346.4	273.2	26.8	340.0	1.9	
Gross Margin	312.3	278.8	12.0	285.3	9.5	
Gross margin (%)	47.4	50.5	-310 bps	45.6	179 bps	
Other expense	198.6	162.5	22.2	177.9	11.6	
EBITDA	113.7	116.2	-2.2	107.4	5.9	
EBITDA Margin (%)	17.3	21.1	-380 bps	17.2	0 bps co p	BITDA margin remains flat sequntially as sub-contract cos ontinues as per business specific requirements & one tim rovision of doubtful debts
Depreciation & amortisation	19.6	10.6	85.7	17.1	14.6 D ad	BA increased on account of increased amotization of MS cquisition
EBIT	94.1	105.7	-10.9	90.3	4.2	
EBIT Margin (%)	14.3	19.1	-486 bps	14.4	-15 bps	
Other income (less interest)	-2.2	4.1	-153.4	1.7	-233.1	
PBT	91.9	109.8	-16.3	92.0	-0.1	
Tax paid	24.8	26.4	-6.0	31.1	-20.3	
PAT	67.1	83.4	-19.6	86.2	-22.1 P	AT in Q2 was higher on account of higher other income

Source: Company, ICICI Direct Research


		FY23E			FY24E			FY25E	Comments
(₹ Crore)	Old	New	% Change	Old	New	% Change	Old	New	% Change
Revenue	2,442.0	2,266	-7.2	2,742	2,525	-7.9	3,110	2,768	-11.0 Numbers cut on slower growth in markets
EBITDA	464.0	408	-12.1	526	462	-12.2	603	518	-14.2
EBITDA Margin (%)	19.0	18.0	-100 bps	19.2	18.3	-90 bps	19.4	18.7	-70 bps Margins cut on normalisation of expenses
PAT	293	263	-10.0	344	311	-9.6	394	349	-11.4
EPS (₹)	102.9	87.6	-10.0	120.9	103.3	-9.6	138.5	116.1	-11.4

Source: Company, ICICI Direct Research


Key Metrics




Source: Company, ICICI Direct Research




Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research






Exhibit 8: Health vertical recover on favourable basis in Q3 50.0 33.6 36.7 40.0 30.0 17.5 14.4 20.0 10.0 (0.3) (16.6) 15.7) (10.0) (2.9 (20.0) (30.0) **01FY22 04FY22** 02FY23 03FY23 02FY22 01FY23 03FY21 04FY21 **03FY22** Health Revenue QoQ Growth (%)

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Resea

Company Update | Mastek Ltd

220.0 210.0 200.0 190.0 180.0

170.0



Exhibit 9: 12-month order backlog up by 5.3% QoQ

187.

02FY23

206.

03FY23

3.6

03FY23

2.8

02FY23

Source: Company, ICICI Direct Research




Exhibit 13: Top five client's revenue growth trend

(4.2)

02FY22

01FY22

(5.5)

03FY22

Top 5 QoQ revenue growth (%)

10.8

04FY22

0.0

Q1FY23

03FY21 6 11 04FY21 6 11 01FY22 8 01 02FY22 11 04FY22 19 04FY23 21 01FY23 21

Exhibit 12: Fortune 1000/ Forbes clients trend

Source: Company, ICICI Direct Research

20.1

Q4FY21

Source: Company, ICICI Direct Research

25.0

20.0

15.0

10.0

5.0

(5.0)

(10.0)

(15.0)

22

5.

03FY21


Source: Company, ICICI Direct Research



Fortune 1000 Clients/ Forbes

Source: Company, ICICI Direct Research

Exhibit 10: LTM attrition continues to moderate



ICICI Direct Research

03FY23

02FY23

Source: Company, ICICI Direct Research

30

25

20

Financial summary

xhibit 15: Profit and lo	ss statem	ent		₹ cror
(Year-end March)	FY22	FY23E	FY24E	FY25E
Net Sales	2,184	2,266	2,525	2,768
Growth (%)	27	4	11	10
COGS (employee expenses)	1,095	1,224	1,356	1,481
Other expenses	626	634	707	769
Total Operating Expenditure	1,721	1,858	2,063	2,250
EBITDA	463	408	462	518
Growth (%)	27	(12)	13	1:
Depreciation	43	62	69	7
Net Other Income	28	67	95	11
PBT	448	413	488	55
Total Tax	115	103	122	13
Exceptional item	-	-	-	
Adjusted PAT	295	263	311	349
Growth (%)	41	(11)	18	1:
Adjusted EPS (₹)	103.8	87.6	103.3	116.

Exhibit 16: Cash flow stateme	nt			₹ crore
(Year-end March)	FY22	FY23E	FY24E	FY25E
Profit before tax	333	367	433	488
Add: Depreciation	43	62	69	76
(Inc)/dec in Current Assets	(175)	(28)	(88)	(83)
Inc/(dec) in CL and Provisions	66	40	127	120
Taxes paid	(109)	(103)	(122)	(138)
CF from operating activities	273	302	364	401
(Inc)/dec in Inv. (+) Int inc (+) Goodwill	464	75	103	120
(Inc)/dec in Fixed Assets	(484)	(34)	(38)	(42)
CF from investing activities	(20)	41	65	78
Issue/(Buy back) of Equity	2	-	-	-
Dividend paid & dividend tax	(48)	(47)	(56)	(63)
Others	(75)	8	8	8
CF from financing activities	(128)	(52)	(60)	(67)
Net Cash flow	119	291	369	412
Exchange difference	(6)	-	-	-
Opening Cash	608	727	1,017	1,387
Closing Cash	727	1,017	1,387	1,799

16.1 Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

xhibit 17: Balance sh	eet			₹ crore
(Year-end March)	FY22	FY23E	FY24E	FY25E
Liabilities				
Equity Capital	15	15	15	15
Reserve and Surplus	1,056	1,272	1,527	1,813
Total Shareholders funds	1,071	1,287	1,542	1,829
Minority interest	150	196	251	318
Total Debt	190	190	190	190
Other liabilities	294	305	339	372
Total Liabilities	1,706	1,979	2,323	2,708
Assets				
Total Fixed Assets	841	825	805	783
Investments	52	52	52	52
Other non current assets	79	80	81	82
Debtors	436	452	504	552
Loans and Advances	-	-	-	-
Cash & investments	782	1,072	1,441	1,854
Other current assets	298	309	344	377
Total Current Assets	1,515	1,833	2,289	2,783
Current liabilities	755	783	873	957
Provisions	28	29	32	35
Total Current Liabilities	783	812	905	992
Net Current Assets	733	1,021	1,384	1,791
Application of Funds	1,706	1,978	2,323	2,708

Source: Company, ICICI Direct Research

share data (₹) n EPS	FY22 103.8 122.0 376.8	FY23E 87.6 108.3	FY24E 103.3	FY25E
	122.0			116
n EPS	122.0			116
n EPS		108.3	400 -	110.
	376.8		126.4	141.
		428.1	512.8	608.
	19.0	15.8	18.6	20.
n Per Share	262.4	338.3	461.0	598.
erating Ratios (%)				
DA Margin	21.2	18.0	18.3	18.
Margin	20.5	18.2	19.3	20.
Margin	13.5	11.6	12.3	12.
ntory days	-	-	-	-
tor days	73	73	73	7
litor days	28	28	28	2
urn Ratios (%)				
	27.5	20.5	20.1	19.
E	26.7	21.2	21.3	20.
;	45.4	38.1	44.5	51.
uation Ratios (x)				
	16.3	19.3	16.4	14.
EBITDA	9.1	9.7	7.7	6.
Net Sales	1.9	1.7	1.4	1.
ket Cap / Sales	2.2	2.1	1.9	1.
e to Book Value	4.4	4.0	3.3	2.
vency Ratios				
t/EBITDA	0.4	0.5	0.4	0.
t / Equity	0.2	0.1	0.1	0.
ent Ratio	0.9	0.9	0.9	0.
k Ratio	0.9	0.9	0.9	0.

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sameer Pardikar, MBA Sujay Chavan MMS, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report. In the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management. etc. ("associates"). the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may note be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and returm on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking attements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.